Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) recently announced that the U.S. Food and Drug Administration has granted approval of its New Drug Application (NDA) for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is...
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), a commercial-stage biopharmaceutical company, is slated to replace ManTech International Corp. (NASDAQ: MANT) in the S&P SmallCap 600 before the opening of trading on Thursday, September 15. The company develops novel medicines for rare chronic neuromuscular and neurological diseases. Its main...
Positive Results from Phase 3 trial of Sabizabulin Veru, Inc. (NASDAQ: VERU) announced the publication of results from a Phase 3 study evaluating the safety and efficacy of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome...
